Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06118957 · ClinicalTrials.gov registry record · Phase 2
Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery
A Phase 2 study of Thromboembolism, sponsored by University of Utah.
- Completed
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT06118957 is a Phase 2 study of Thromboembolism that has completed, run by University of Utah. The registered enrollment target is 64 participants, below the 307-participant average among 8 other Thromboembolism trials with a reported enrollment target (79% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06118957, a Phase 2 study of Thromboembolism, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the allocated treatment group.
Conditions Studied
Interventions
- DRUG Enoxaparin
Study Locations (1)
Utah
- University of Utah - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2023-10-11 |
| Est. Completion | 2024-07-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06118957
The ClinicalTrials.gov registry entry for NCT06118957 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 307-participant average among 8 other Thromboembolism trials with a reported enrollment target (79% lower). The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Thromboembolism appearing as the primary indexed condition, and to 1 intervention - of which Enoxaparin is the first listed.
NCT06118957 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT06118957 about?
NCT06118957 is a clinical study titled "Low Molecular Weight Heparin or no Treatment Following Cesarean Delivery". The aim of this study is to evaluate the feasibility of randomizing individuals to low molecular weight heparin (enoxaparin) or no treatment following cesarean delivery. The investigators hypothesize that among eligible individuals, at least 35% will enroll, undergo randomization, and complete the a...
What is the current status of trial NCT06118957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2023-10-11. Estimated completion is 2024-07-01.
What conditions does trial NCT06118957 study?
This clinical trial studies the following conditions: Thromboembolism.
What interventions are being tested in trial NCT06118957?
The interventions under investigation include: Enoxaparin (DRUG).
Who is sponsoring clinical trial NCT06118957?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06118957 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thromboembolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Preoperative Tranexamic Acid (TXA) to Prevent Bleeding in Patients Undergoing Major Colorectal Surgery
RECRUITING · Phase 2
-
Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer
COMPLETED · Phase 2
-
In Vivo Detection of Circulating Clots in Patients With Thromboembolism
RECRUITING · NA
-
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
ACTIVE NOT RECRUITING · Phase 4
-
The Clinical and Economic Impact of Pharmacogenomic Testing of Warfarin Therapy in Typical Community Practice Settings
COMPLETED
-
Impact of Prophylactic Low-molecular Weight Heparin Dosing on Clotting Parameters Following Cesarean Delivery
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.